What is Relmada Therapeutics, Inc.'s EBITDA?

Relmada Therapeutics, Inc. (RLMD) reported EBITDA of -$26.46M in Q2 2021.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Relmada Therapeutics, Inc. RLMD EBITDA

EBITDA at other companies

CG OncologyCGON

-$65.55M-55.4%

ArvinasARVN

-$63.1M-188%

Replimune GroupREPL

-$71.07M-9.3%

ImmunomeIMNM

-$58.73M-33.4%

Johnson & JohnsonJNJ

——

Merck & Co.MRK

——

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Calculated from Relmada Therapeutics, Inc.’s reported figures.

−$26.5Mebit+

$452.0Depreciation Depletion & Amortization

=-$26.46M

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed August 11, 2022, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s EBITDA?: Relmada Therapeutics, Inc. (RLMD) reported EBITDA of -$26.46M in Q2 2021.
What does EBITDA mean?: Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.